A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker
The world’s worst outbreak of Ebola has killed nearly 1,000 people in
There is no proven cure or vaccine to prevent infection with Ebola and the scale of the current outbreak has prompted the
GSK’s experimental vaccine has already produced promising results in animal studies involving primates and it is now due to enter initial Phase I testing in humans, pending approval from the
A company spokeswoman said on Sunday that the trial should get underway “later this year”, while GSK’s partner the
Even if is fast-tracked, however, and emergency procedures are put in place, the new vaccine could not be ready for widespread deployment before 2015 – even assuming it works as well as hoped.
“It is right at the beginning of the development journey and still has a very long way to go,” the GSK official said, declining to be drawn on a possible timeline for launch.
The investigational vaccine is based on a chimpanzee adenovirus into which two Ebola genes have been inserted, which means it contains no infectious Ebola virus material. Adenoviruses are best known for causing the common cold.
Once the vaccine enters a cell and delivers its genetic payload, the two gene inserts produce a protein that generates an immune response in the body – but the adenovirus carrying the genes does not replicate further.
GSK acquired the vaccine after buying Swiss-based biotech company Okairos for
The U.S. NIAID – part of the
Most Popular Stories
- Alabama House Speaker Arrested on Felony Ethics Charges
- 'Fury' Blows 'Gone Girl' Out of the Box Office
- Microsoft's Cloud Platform Shines
- Turkey to Help Kurds Reach Fight in Kobani
- German Intelligence Blames Ukraine Rebels for MH17
- ISIS Seeks to Expand Terror War
- Perez Leads Push for Obama's Job Proposals
- 2016 Camaro Shrinks, Moves to Caddy Platform
- Prius Drivers Battle Stereotypes
- Clinton Rallies Early Vote for Landrieu